Evidence map›Paper›PMID 37398677›Full record

ArticleFrontiers in immunology2023

Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats.

Tetsuya Tajima, Koichiro Hata, Jiro Kusakabe, Hidetaka Miyauchi, Joshua Sam Badshah, Shoichi Kageyama, Xiangdong Zhao, Sung-Kwon Kim, Tatsuaki Tsuruyama, Varvara A Kirchner and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Tetsuya TajimaDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Koichiro HataDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Jiro KusakabeDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hidetaka MiyauchiDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Joshua Sam BadshahDepartment of Surgery , Division of Abdominal Transplantation, Stanford University School of Medicine, Stanford, CA, United States.
Shoichi KageyamaDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Xiangdong ZhaoDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sung-Kwon KimAlexion Pharmaceuticals Inc., New Haven, CT, United States.
Tatsuaki TsuruyamaDepartment of Drug Discovery Medicine, Pathology Division, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Varvara A KirchnerDepartment of Surgery , Division of Abdominal Transplantation, Stanford University School of Medicine, Stanford, CA, United States.
Takeshi WatanabeDivision of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Shinji UemotoDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Etsuro HatanoDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPStanford University · USAlexion Pharmaceuticals (United States) · USShiga University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-mediated rejection (AMR) remains a refractory rejection after donor-specific antibody (DSA)-positive or blood-type incompatible liver transplantation (LT), even in the era of pre-transplant rituximab desensitization. This is due to the lack of not only effective post-transplant treatments but also robust animal models to develop/validate new interventions. Orthotopic LT from male Dark Agouti (DA) to male Lewis (LEW) rats was used to develop a rat LT-AMR model. LEW were pre-sensitized by a preceding skin transplantation from DA 4-6 weeks before LT (

Indexed as

Kidney TransplantationLiver TransplantationAnimalsComplement C5Graft RejectionIsoantibodiesMaleRatsRats, Inbred LewComplement C5Isoantibodiesantibody-mediated rejection (AMR)complement 5donor-specific antibody (DSA)eculizumabliver transplantation

Identifiers

PMID37398677
PMCPMC10313232
OpenAlexW4380986188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.